会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • INORGANIC GEL FOR CONTROLLED RELEASING OF FRAGRANCE AND DISINFECTANT
    • 无机凝胶用于控制释放的消除和消毒
    • US20130287723A1
    • 2013-10-31
    • US13997795
    • 2011-12-21
    • King Lun YeungWei HanShengli CaoWai Kwong Ching
    • King Lun YeungWei HanShengli CaoWai Kwong Ching
    • A61L9/04
    • A61L9/048A01N25/04A01N65/00A01N65/28A01N65/36A01N65/48A61L9/012A01N25/18A01N59/00A01N65/06
    • A gel composition for air freshening or disinfecting, comprising a silicon alkoxide or colloidal silica, a volatile or gaseous fragrance and/or disinfectant, water, an acid or base catalyst, a water-soluble solvent, and optionally other volatile components and additives, and a method for preparing the same. The gel can be transparent or colored, has a homogeneous texture and a soft to rigid structure, and contains volatile or gaseous components from 0 vol % to 85 vol % for scented materials (fragrance and oils) and/or 0-8000 ppm of disinfectant, which are released at a steady rate under ambient conditions, controlled by the shape and opening of the gel container. Botanicals or plastic decorations may be added into the gel to improve its aesthetic appeal. The preparation method is easier and requires less energy consumption and the gel is used as an air freshener or disinfectant.
    • 用于空气清新或消毒的凝胶组合物,其包含硅醇盐或胶体二氧化硅,挥发性或气态香料和/或消毒剂,水,酸或碱催化剂,水溶性溶剂和任选的其它挥发性组分和添加剂,以及 其制备方法。 凝胶可以是透明的或着色的,具有均匀的质地和柔软至刚性的结构,并且含有挥发性或气体组分,对于香味材料(香料和油)为0vol%至85vol%,和/或0-8000ppm的消毒剂 ,其在环境条件下以稳定的速率释放,由凝胶容器的形状和开口控制。 可以将植物性或塑料装饰品添加到凝胶中以改善其美学吸引力。 制备方法更容易,需要更少的能量消耗,凝胶用作空气清新剂或消毒剂。
    • 5. 发明授权
    • Use of midkine protein and the protein-containing medical device
    • 使用中期蛋白和含蛋白质的医疗器械
    • US09283300B2
    • 2016-03-15
    • US13322443
    • 2010-05-25
    • Wei HanZhonghui Zhang
    • Wei HanZhonghui Zhang
    • A61K38/17A61P19/02A61L27/54A61L27/24A61L27/22A61K38/18A61F2/30
    • A61L27/227A61F2/30756A61F2002/30677A61K38/18A61L27/54A61L2300/252A61L2300/414A61L2430/06
    • The applications and medical devices of Midkine in the field of biotechnology are described in this invention. This invention describes the applications of the protein as follow in (a) or (b) in preparing drugs for promoting cartilage growth or treating cartilage diseases, the protein as a growth factor for promoting chondrocyte proliferation, or medical devices containing this protein: (a) the protein whose amino acid sequence is shown as SEQ ID NO.1; (b) the proteins whose amino acid sequence have at least 60% homology comparing with amino acid sequence described in (a). The present invention is different from the present knowledge of MK and its related proteins. The experimental results demonstrated that MK promotes proliferation of three types of chondrocytes and is used for preparing drugs for treating cartilage disease. It may provide new therapy for treating cartilage diseases clinically, and new technology for expansion of chondrocytes in vitro for cartilage tissue engineering.
    • 本发明描述了Midkine在生物技术领域的应用和医疗设备。 本发明描述了如下(a)或(b)中的蛋白质在制备用于促进软骨生长或治疗软骨疾病的药物中的应用,所述蛋白质作为促进软骨细胞增殖的生长因子,或含有该蛋白质的医学装置:(a )其氨基酸序列显示为SEQ ID NO.1的蛋白质; (b)与(a)中所述的氨基酸序列相比,其氨基酸序列具有至少60%同源性的蛋白质。 本发明与MK及其相关蛋白质的现有知识不同。 实验结果表明,MK促进三种软骨细胞增殖,用于制备治疗软骨疾病的药物。 可能提供临床治疗软骨疾病的新疗法,软骨组织工程体外软骨细胞扩增的新技术。
    • 7. 发明授权
    • Thiophene derivatives as factor XIa inhibitors
    • 噻吩衍生物作为因子XIa抑制剂
    • US08466295B2
    • 2013-06-18
    • US12097068
    • 2006-12-13
    • Wei Han
    • Wei Han
    • C07D231/56C07D333/22A61K31/415A61K31/38
    • C07D333/24C07D333/28C07D409/04
    • The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, L1, R3, and R11 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    • 本发明提供式(I)的化合物或其立体异构体,互变异构体,药学上可接受的盐,溶剂合物或前药,其中变量A,L1,R3和R11如本文所定义。 式(I)的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶,因子Xa,因子XIa,因子IXa,因子VIIa和/或血浆激肽释放酶。 特别地,它涉及作为选择性因子XIa抑制剂的化合物。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
    • 8. 发明授权
    • DC to DC converter and method for reducing overshoot
    • DC到DC转换器和减少过冲的方法
    • US08330442B2
    • 2012-12-11
    • US12710860
    • 2010-02-23
    • Wei HanChing-Ji LiangTao Liu
    • Wei HanChing-Ji LiangTao Liu
    • G05F1/40
    • H02M3/158
    • A DC to DC converter includes a control circuit, a gate driver circuit, and a power stage circuit. The control circuit receives and compares a DC output voltage. When the DC output voltage lower than a first threshold voltage, a PWM signal with a first frequency is outputted, and when the DC output voltage higher than the first threshold voltage, the PWM signal with a second frequency is outputted. The second frequency is higher than the first frequency. The gate driver circuit receives the PWM signal and converts the PWM signal to a first driving signal and a second driving signal. The power stage circuit converts a DC input voltage to the DC output voltage according to the first driving signal and the second driving signal.
    • DC-DC转换器包括控制电路,栅极驱动电路和功率级电路。 控制电路接收并比较直流输出电压。 当DC输出电压低于第一阈值电压时,输出具有第一频率的PWM信号,并且当DC输出电压高于第一阈值电压时,输出具有第二频率的PWM信号。 第二频率高于第一频率。 栅极驱动电路接收PWM信号,并将PWM信号转换为第一驱动信号和第二驱动信号。 功率级电路根据第一驱动信号和第二驱动信号将直流输入电压转换为直流输出电压。
    • 10. 发明授权
    • Programmable logic device with built in self test
    • 可编程逻辑器件内置自检
    • US07944765B1
    • 2011-05-17
    • US12626289
    • 2009-11-25
    • Wei HanYoshita YerramilliLoren McLauryWarren Juenemann
    • Wei HanYoshita YerramilliLoren McLauryWarren Juenemann
    • G11C29/00
    • G11C29/08G01R31/318519G11C2029/0401
    • In one embodiment of the invention, an integrated circuit such as a programmable logic device includes volatile memory, nonvolatile memory, and a data shift register for reading data from the nonvolatile memory and for reading data from and writing data to the volatile memory. A built in self test (BIST) circuit is operable to test the nonvolatile memory without the data shift register reading data from the nonvolatile memory. The BIST circuit may include a finite state machine for performing at least one of the following tests on the nonvolatile memory: bulk erase, bulk program; margin bulk program; and/or margin bulk erase. A memory controller responsive to the finite state machine is operable to write data to and read data from the nonvolatile memory during testing of the nonvolatile memory.
    • 在本发明的一个实施例中,诸如可编程逻辑器件的集成电路包括易失性存储器,非易失性存储器和用于从非易失性存储器读取数据并用于从易失性存储器读取数据并将数据写入到易失性存储器的数据移位寄存器。 内置自检(BIST)电路可用于测试非易失性存储器,而数据移位寄存器从非易失性存储器读取数据。 BIST电路可以包括用于对非易失性存储器执行以下测试中的至少一个的有限状态机:批量擦除,批量程序; 保证金批发方案; 和/或边缘批量擦除。 响应于有限状态机的存储器控​​制器可用于在非易失性存储器的测试期间将数据写入非易失性存储器并从其读取数据。